LEADER 00782nam0-22003011i-450-
001 990003229920403321
035   $a000322992
035   $aFED01000322992
035   $a(Aleph)000322992FED01
035   $a000322992
100   $a20000920d1971----km-y0itay50------ba
101 0 $aita
102   $aIT
200 1 $aUrban Studies$eAn Introductory Reader$fEdited by Louis K. Loewenstein.
210   $aNew York$cFree Press$d\c\\1971.
215   $aXXVI, 539 p.$d23 cm
676   $a16320
676   $a20120
676   $a20140
702  1$aLoewenstein,$bLouis K.
801  0$aIT$bUNINA$gRICA$2UNIMARC
901   $aBK
912   $a990003229920403321
952   $a16320 LOE$b3679/I$fSES
959   $aSES
996   $aUrban Studies$9449162
997   $aUNINA
DB    $aING01

LEADER 01384nam  2200385Ia 450 
001 9910696949703321
005 20230902162120.0
035   $a(CKB)5470000002383395
035   $a(OCoLC)550631292
035   $a(EXLCZ)995470000002383395
100   $a20100310d2004      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $ebrief summary : disclosing risk information in consumer-directed print advertisements
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Researcy :$cCenter for Biologics Evaluation and Research,$d[2004]
215   $a1 electronic resource (8 pages)
300   $a"Draft guidance."
300   $a"DDMAC."
300   $a"January 2004."
517   $aGuidance for industry 
606   $aAdvertising$xDrugs$zUnited States
606   $aDrugs$xSide effects$zUnited States
615  0$aAdvertising$xDrugs
615  0$aDrugs$xSide effects
712 02$aCenter for Drug Evaluation and Research (U.S.)
712 02$aCenter for Biologics Evaluation and Research (U.S.)
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910696949703321
996   $aGuidance for industry$93434577
997   $aUNINA